Parsatuzumab

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameParsatuzumab
Drug Alias NameAnti-EGFL7 (Genentech)RG-7414RO-5490248M-0444AM-444A +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionEpidermal growth factor-like protein 7 inhibitors
TargetsEpidermal growth factor-like protein 7
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungColorectal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumUnited States +[9] 
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGenentech Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGenentech Inc
Active IndicationsN/A
Inactive IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungColorectal Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A